Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. MethylGene was formed in 1996 by Hybridon Inc and three Canadian institutional investors. In 2001, Hybridon sold all of its shares in MethylGene for an aggregate purchase price of US$7.2 million. MethylGene is now a private biopharmaceutical company striving to discover and develop novel drugs against enzyme targets in cancer and infectious diseases. The company has built strong core competencies in chemistry and biology with particular strengths in functional genomics, rational drug design and medicinal chemistry.

MethylGene employs an integrated array of technologies to create a broad pipeline of novel pharmaceuticals to fight cancer and antibiotic resistance. These technologies include target validation through functional genomics, rational drug design and lead compound optimisation, utilising combinatorial and medicinal chemistry. This drug discovery engine has allowed the company to establish a substantial product pipeline in a relatively short period of time and is renewable, allowing the company to continuously feed this pipeline with new products.

MethylGene's drug-discovery strategy is focused on enzyme targets that are novel, identified clearly as responsible for disease and commercially attractive. When selecting novel targets, the company aims for a leadership position in the field, as has been achieved with DNA methyltransferase (DNMT) and histone deacetylase (HDAC), its first two targets.